Blood Group Typing Market by Product (Consumables, Instruments, Services), Test Type (ABO, Antigen, Antibody, HLA), Technique (Assay-based, PCR, Microarray, Massively Parallel Sequencing), End User (Hospital, Blood Banks), Region - Global Forecast to 2028
The blood group typing market is valued at an estimated USD 2.0 billion in 2023 and is projected to reach USD 3.0 billion by 2028, at a CAGR of 8.7% during the forecast period. Severe post-partum hemorrhage (bleeding during delivery or after childbirth) is the leading cause of maternal mortality worldwide. Additionally, childhood anemia, trauma, and congenital blood disorders are other emergency conditions requiring blood transfusions. Urgent and timely treatment is required to manage these patients, including transfusion of blood and blood products. The overall increase in the number of blood transfusions is leading to the increased adoption of blood group typing methods in order to ensure the safety and compatibility of the transfused blood. This is driving the overall growth of the market.
“Antibody screening segment accounted for the highest growth rate in the blood group typing market, by test type, during the forecast period.”
The blood group typing market is bifurcated into ABO blood tests & Rh typing, antibody screening, HLA typing, cross-matching tests, and antigen typing on the basis of test type. The antibody screening segment in the blood group typing market is experiencing substantial growth, largely driven by the increasing incidence of diseases such as autoimmune disorders and cancers. The use of antibody screening methods is also growing due to the rising focus on R&D in antigen-specific therapies in response to the increasing incidence of chronic diseases.
“PCR-based and microarray techniques segment accounted for the highest growth rate in the blood group typing market, by techniques, during the forecast period.”
The global blood group typing market is bifurcated into assay-based techniques, PCR-based and microarray techniques, massively parallel sequencing, and other techniques. The PCR-based and microarray techniques segment is currently witnessing the highest growth rate within the blood group typing market. PCR-based techniques have emerged as powerful tools to accurately identify and characterize rare blood group antigens at the genetic level. However, PCR methods have limited throughput and multiplex capacity. To overcome these limitations, microarray platforms have been developed. Microarray platforms give more detailed information about blood group antigens than basic PCR methods. Owing to the advantages of these methods, such as high accuracy over traditional methods, their adoption is increasing among end users.
“Asia Pacific: The fastest-growing region blood group typing market”
The global blood group typing market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to witness the highest growth during the forecast period due to factors such as government efforts to increase awareness about the importance of blood donations and regular health check-ups, continuously rising healthcare expenditures, an increasing number of hospitals in India and China, and strengthening research bases for diagnostic procedures across India, China, and Japan. Furthermore, supportive government regulations will further aid the growth of this market during the forecast period.
The break-up of the profile of primary participants in the blood group typing market:
By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%
The key players in this market are Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), Thermo Fisher Scientific Inc. (US), Immucor, Inc. (US), Danaher (US), Merck KGaA (Germany), Quotient Limited (Switzerland), Novacyt (France), BAG Health Care GmbH (Germany), Rapid Labs Ltd (UK), Agena Bioscience, Inc. (US), Biorex Diagnostics (UK), HUMAN Gesellschaft für Biochemica und Diagnostica mbH (Germany), Prestige Diagnostics (UK), Span Diagnostics SARL (France), DIALAB GmbH (Austria), Lorne Laboratories Limited (UK), Atlas Medical GmbH (Germany), Torax Biosciences Limited (Northern Ireland), Fortress Diagnostics (UK), AXO Science (France), Maxwin Health Care Pvt. Ltd. (India), Anamol Laboratories Pvt. Ltd. (India), J. Mitra & Co. Pvt. Ltd. (India), and MedSource Ozone Biomedicals Pvt. Ltd. (India).
Research Coverage:
This research report categorizes the blood group typing market by product & service (consumables, instruments, and services & software), test type (ABO blood tests & Rh typing, antibody screening, HLA typing, cross-matching tests, and antigen typing), technique (assay-based techniques, PCR-based and microarray techniques, massively parallel sequencing, and other techniques), end user (hospitals, blood banks, clinical laboratories, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, and opportunities, influencing the growth of the blood group typing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the blood group typing market. Competitive analysis of upcoming startups in the blood group typing market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall blood group typing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, and opportunities.
The report provides insights on the following pointers:
Analysis of key drivers (Increasing prevalence of chronic diseases and rising number of surgical procedures necessitating need for blood donations, growing number of road accidents, emergencies, and trauma cases necessitating blood transfusions, increasing demand for blood group typing in prenatal testing, high usage of blood group typing in forensic sciences, extensive R&D in blood typing, and stringent regulatory standards for blood transfusion), restraints (emergence of blood alternatives), and opportunities (growth opportunities in emerging economies) influencing the growth of the blood group typing market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the blood group typing market.
Market Development: Comprehensive information about lucrative markets – the report analyses the blood group typing market across varied regions.
Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the blood group typing market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), Thermo Fisher Scientific Inc. (US), and Immucor, Inc. (US), among others in the blood group typing market strategies.